Literature DB >> 31830133

Human immunity to Toxoplasma gondii.

Daniel Fisch1, Barbara Clough1, Eva-Maria Frickel1.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 31830133      PMCID: PMC6907746          DOI: 10.1371/journal.ppat.1008097

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


× No keyword cloud information.

Innate immune response and Toxoplasma detection

Toxoplasma gondii (Tg) is an apicomplexan parasite able to invade any nucleated cell in warm-blooded animals. Approximately 30% of all humans harbour a chronic and asymptomatic infection [1]. Health risks include severe encephalitis in the immunocompromised, congenital defects, and ocular disease prevalent mostly in South America [2]. Felines are Tgs definitive host, and human infection occurs mostly through consumption of contaminated food or water [3]. Following ingestion, an initial site of infection develops in the tissue surrounding the intestines, causing inflammation. From there, Tg disseminates via the blood stream, establishing a chronic infection and entering immune-privileged sites, including the brain [4]. As humans are dead-end hosts, the interaction between host and parasite differs from that of rodents, and it is surprising how little is known about several levels of the human response to infection [5,6]. Hence, the use of mice as a model can only contribute partially to the study of the human response to Tg-infection. In this review, we explore data available on the human immune response to Tg-infection on a systemic level, in the response of individual cells, and to the complete control of infection. We also discuss Tg entering immune-privileged sites—causing disease in healthy individuals—and propose areas of interest for future research. The innate immune system is the first to respond to infection with production of interleukin (IL)-12 by neutrophils, dendritic cells (DCs), and monocytes but not macrophages that have phagocytosed Tg [7-9]. Intracellular sensing differs from mice as humans do not have functional equivalents to murine toll-like receptors (TLRs)11 and 12 [10,11]. Monocytes sense Tg-infection through Alarmin S100A11 secreted from infected cells, which results in production of the chemokine (C-C motif) ligand 2 (CCL2) [12]. Additionally, cytosolic recognition of Tg in monocytes relies partly on the NLR family pyrin domain containing 1 (NLRP1) and NLRP3 inflammasome, leading to cell death at later time points and early secretion of IL-1β [13,14]. Interestingly, neutrophils and macrophages do not sense Tg-infection in the same way since they do not display pyroptosis or IL-1β secretion [14,15]. Based on in vivo mouse and human in vitro models, cytokine production in the inflamed tissue triggers interferon gamma (IFNγ)-production by T helper cell (Th)1 and natural killer (NK) cells, which leads to a robust adaptive Th1-immune response to control Tg-infection (see Fig 1) [16,17].
Fig 1

Systemic and cellular human response to Toxoplasma infection.

Left: Systemic response to Tg-infection: Infected cells and cells that have phagocytosed Tg parasites at a site of infection sense the presence of the pathogen via the indicated PRRs and defence proteins and react by production of proinflammatory cytokines and chemokines like CCL2, IL-1β, and IL-12. This cytokine presence will trigger IFNγ–production by Th1 and NK cells. Right: Cellular response to Tg-infection: IFNγ and potentially other cytokines trigger infected cells to mount a cell-intrinsic defence against the PV. Mechanisms include ubiquitin-driven non-canonical autophagy of the entire PV and growth stunting; marking the PV with Ub, LAMP1, and the autophagy adapter proteins NDP52 and p62, followed by acidification of the vacuoles and killing of the parasite; recruitment of GBP1 to Tg vacuoles to disrupt them and expose the parasite within or growth restriction of Tg by GBP1 without translocation to the vacuole; and host cell death in response to opened PVs and leakage of pathogen-associated molecular patterns into the cytosol for detection by PRRs. The exact mechanisms highly depend on the cell type and the Tg strain infecting the cells. AIM, absent in melanoma 2; ASC, apoptosis-associated speck-like protein containing a CARD; CASP, caspase; CCL, chemokine (C-C motif) ligand; GBP, guanylate binding protein; IL, interleukin; IFNγ, interferon gamma; LAMP, lysosome-associated membrane protein; NDP52, nuclear domain 10 protein 52; NK, natural killer; NLRP, nucleotide-binding oligomerization domain, Leucine rich repeat and Pyrin domain containing; PAMP, pathogen-associated molecular patterns; PRR, pattern recognition receptor; PV, parasitophorous vacuole; Tg, Toxoplasma gondii; Th, T helper cell; TNFα, tumour necrosis factor α; Ub, Ubiquitin.

Systemic and cellular human response to Toxoplasma infection.

Left: Systemic response to Tg-infection: Infected cells and cells that have phagocytosed Tg parasites at a site of infection sense the presence of the pathogen via the indicated PRRs and defence proteins and react by production of proinflammatory cytokines and chemokines like CCL2, IL-1β, and IL-12. This cytokine presence will trigger IFNγ–production by Th1 and NK cells. Right: Cellular response to Tg-infection: IFNγ and potentially other cytokines trigger infected cells to mount a cell-intrinsic defence against the PV. Mechanisms include ubiquitin-driven non-canonical autophagy of the entire PV and growth stunting; marking the PV with Ub, LAMP1, and the autophagy adapter proteins NDP52 and p62, followed by acidification of the vacuoles and killing of the parasite; recruitment of GBP1 to Tg vacuoles to disrupt them and expose the parasite within or growth restriction of Tg by GBP1 without translocation to the vacuole; and host cell death in response to opened PVs and leakage of pathogen-associated molecular patterns into the cytosol for detection by PRRs. The exact mechanisms highly depend on the cell type and the Tg strain infecting the cells. AIM, absent in melanoma 2; ASC, apoptosis-associated speck-like protein containing a CARD; CASP, caspase; CCL, chemokine (C-C motif) ligand; GBP, guanylate binding protein; IL, interleukin; IFNγ, interferon gamma; LAMP, lysosome-associated membrane protein; NDP52, nuclear domain 10 protein 52; NK, natural killer; NLRP, nucleotide-binding oligomerization domain, Leucine rich repeat and Pyrin domain containing; PAMP, pathogen-associated molecular patterns; PRR, pattern recognition receptor; PV, parasitophorous vacuole; Tg, Toxoplasma gondii; Th, T helper cell; TNFα, tumour necrosis factor α; Ub, Ubiquitin.

Cellular response to Toxoplasma infection

The human cellular response to Tg-infection is highly dependent on cell type [18] and the infecting strain of Tg [19]. Interestingly, although the principal cytokine controlling Tg-infection is IFNγ, other cytokines have been implicated. For example, brain microglial cells control Tg growth by production of tumour necrosis factor α (TNFα) and IL-6 [20]. TNFα is proposed to mediate Tg killing in patients with IFNγ receptor 1 (IFNGR1) deficiency, partially compensating for lack of IFNγ-responsiveness [21]. Furthermore, IFNγ-independent control of Tg has been reported via cluster of differentiation (CD)40-induced autophagy of parasitophorous vacuoles (PV) in human macrophages [22], with the caveat that Tg activates epidermal growth factor receptor (EGFR) to combat its own autophagic clearance [23]. It is likely that several different host response pathways act in concert to control Tg-infection. However, for the purposes of this review, we will focus on the role of IFNγ-induced defence mechanisms (see Fig 1). We recently showed that the IFNγ dose-dependent restriction of Tg-infection depends on cell type, with epithelial cells displaying a sharp parasiticidal effect, in contrast to macrophages, fibroblasts, and endothelial cells demonstrating a dose-dependent response [24]. A common initial response is to mark PVs with ubiquitin [24-26], but the ubiquitinated substrate(s) and the E3 ligases involved in this process remain to be defined. Following ubiquitination, epithelial cells control parasites through an incomplete autophagy, involving recruitment of autophagy adapter proteins p62 (SQSTM1) and NDP52 (CALCOCO2) and the autophagy-related protein 8 (Atg8) protein microtubule-associated protein-1A/1B light chain 3 (LC3B), but this fails to mature to autophago-lysosomes [25]. Endothelial cells follow this path up to the recruitment of adapter proteins, but then deviate from it, either by shuttling the marked PV into the endo-lysosomal pathway or directly acidifying the PVs [26]. Both cell types maintain the integrity of the PV and restrict the parasite within. Conversely, macrophages are able to open Tg vacuoles, as we have recently demonstrated [27]. This induces an atypical apoptosis pathway relying on DNA-sensing by absent in melanoma 2 (AIM2) and execution of apoptosis via an apoptosis-associated speck-like protein containing a CARD (ASC)-caspase 8 (CASP8) signalling axis [29], whereas Tg is able to block apoptosis in other human cells [28]. This cell death phenotype is dependent on IFNγ-induced guanylate binding proteins (GBPs), of which GBP1 translocates to Tg vacuoles and releases Tg-derived molecular ligands of cellular receptors [27]. Similarly, GBP1 translocates to Tg vacuoles in mesenchymal stem cells [29] but not in epithelial cells [30]. In both cell types, the protein was able to restrict Tg independent of its recruitment [29,30]. Thus, recruited GBP1 seems to uniquely induce host cell death in macrophages. In contrast to death of macrophages, IFNγ-primed fibroblasts die through an uncharacterised form of cell death [31]. Similar to GBP1’s function in restricting Tg growth remotely from the PV, other cell-intrinsic mechanisms act on Tg from a distance: IFNγ-induced indoleamine-2,3-dioxygenase 1 (IDO) can deplete cells of tryptophan, which slows down growth of tryptophan-auxotrophic Tg [32]. This mechanism can be counteracted by the Tg effector protein inhibitor of STAT1 transcriptional activity (TgIST) [33] and has been shown to be dispensable in human umbilical vein endothelial cells (HUVECs) [34]. In general, the secreted Tg virulence factor TgIST is able to shut down many IFNγ-mediated responses to infection by blocking transcription of IFNγ-induced genes [35,36]. Furthermore, in contrast to mouse cells, nitric oxide was not relevant in restriction of Tg in HUVECs [34]. Parasites that escape within a few hours of entering the host cells may be an important unexplored consequence of IFNγ-dependent host restriction, as has been observed in human fibroblasts and endothelial cells [31]. This phenomenon is difficult to quantitate and may be larger than the 5%–10% reported. Whether the escaped Tg parasites are viable remains an open question. Taken together, cell-intrinsic defence to Tg-infection not only differs largely between species but also between different cell types, and much work is needed to uncover new mechanisms.

Dissemination in the infected host and entering of immune-privileged sites

While the host responds to Tg-infection with cell death and cytokine production in the infected tissue, some parasites leave the site of primary infection and disseminate in the body [4]. Under pressure from the adaptive immune response, Tg converts to the bradyzoite stage and forms tissue cysts, surviving until death of the host [37]. Tg is believed to travel to immune-privileged sites of the brain and eye and also cross the placenta of an infected woman and infect the foetus congenitally [4]. In primary infections, this can result in abortion or foetal abnormalities such as hydrocephalus and retinochoroiditis [2,3]. Retinochoroiditis is the most common form of congenital toxoplasmosis, with the infection leading to an increase in HIF1α and vascular endothelial growth factor (VEGF) expression, resulting in increased vascularisation [38]. An increase in IL-1β, IL-6, granulocyte-macrophagecolony-stimulating factor (GM-CSF), and intercellular adhesion molecule (ICAM)-1 produced by retinal pigment epithelial cells was also described [39]. Intraocular fluid of Tg-infected eyes contain elevated levels of TGF-β [40,41], which may modulate the effects of IFNγ that inhibit Tg replication in human primary retinal pigment epithelial cells by tryptophan starvation [42]. Differences between French and Colombian clinical cases of ocular toxoplasmosis highlight the importance of understanding disease severity. Decreased intraocular IFNγ and IL-17, and higher IL-13 and IL-6 expression were detected in Colombian patients [43], suggesting the increased severity of ocular disease caused by South American strains could be attributed to an inhibition of protection afforded by IFNγ.

Concluding remarks and future studies

The immune response to Tg has been extensively studied in mice. Since mice are an intermediate host to Tg, many mechanisms are unique to this host–pathogen pair and cannot be extrapolated to the human host. Key areas of research for the future are as follows: IFNGR1-deficient patients possibly do not suffer from a higher incidence of Tg-borne disease. Is IFNγ the main cytokine responsible for Tg control in humans in all cell types? South American atypical Tg strains cause ocular toxoplasmosis, but other strains do not cause this disease. What makes these strains unique in being a disease-causing pathogen? Virulence of the clonal Tg strains was defined based on the mouse system and is not transferable to the human host. What are Tg virulence factors in humans and which strains are they derived from? Different human cell types show varying responses to Tg-infection. Why is there no unified defence strategy? Recruitment of host effectors to vacuole is only 30%–50% at any one time point. Which host defence mechanisms operate away from the vacuole? How many Tg tachyzoites escape acute phase control? What host response triggers parasites to escape the cell and are they still viable? These and other open points will have to be addressed in future studies to uncover new mechanisms of the human response to Tg-infection.
  43 in total

Review 1.  Immunoregulatory mechanisms of the eye.

Authors:  J W Streilein; G A Wilbanks; S W Cousins
Journal:  J Neuroimmunol       Date:  1992-08       Impact factor: 3.478

2.  Toxoplasma Effector Recruits the Mi-2/NuRD Complex to Repress STAT1 Transcription and Block IFN-γ-Dependent Gene Expression.

Authors:  Philipp Olias; Ronald D Etheridge; Yong Zhang; Michael J Holtzman; L David Sibley
Journal:  Cell Host Microbe       Date:  2016-07-13       Impact factor: 21.023

Review 3.  Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases.

Authors:  J Xiao; R H Yolken
Journal:  Acta Physiol (Oxf)       Date:  2015-01-28       Impact factor: 6.311

4.  Defining host-pathogen interactions employing an artificial intelligence workflow.

Authors:  Daniel Fisch; Artur Yakimovich; Barbara Clough; Joseph Wright; Monique Bunyan; Michael Howell; Jason Mercer; Eva Frickel
Journal:  Elife       Date:  2019-02-12       Impact factor: 8.140

5.  Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan.

Authors:  E R Pfefferkorn
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

Review 6.  Toxoplasma gondii: transmission, diagnosis and prevention.

Authors:  D Hill; J P Dubey
Journal:  Clin Microbiol Infect       Date:  2002-10       Impact factor: 8.067

7.  Evasion of Human Neutrophil-Mediated Host Defense during Toxoplasma gondii Infection.

Authors:  Tatiane S Lima; Lanny Gov; Melissa B Lodoen
Journal:  MBio       Date:  2018-02-13       Impact factor: 7.867

8.  Toxoplasma gondii-induced activation of EGFR prevents autophagy protein-mediated killing of the parasite.

Authors:  Luis Muniz-Feliciano; Jennifer Van Grol; Jose-Andres C Portillo; Lloyd Liew; Bing Liu; Cathleen R Carlin; Vern B Carruthers; Stephen Matthews; Carlos S Subauste
Journal:  PLoS Pathog       Date:  2013-12-19       Impact factor: 6.823

9.  Severe South American ocular toxoplasmosis is associated with decreased Ifn-γ/Il-17a and increased Il-6/Il-13 intraocular levels.

Authors:  Alejandra de-la-Torre; Arnaud Sauer; Alexander W Pfaff; Tristan Bourcier; Julie Brunet; Claude Speeg-Schatz; Laurent Ballonzoli; Odile Villard; Daniel Ajzenberg; Natarajan Sundar; Michael E Grigg; Jorge E Gomez-Marin; Ermanno Candolfi
Journal:  PLoS Negl Trop Dis       Date:  2013-11-21

10.  Alarmin S100A11 initiates a chemokine response to the human pathogen Toxoplasma gondii.

Authors:  Alexandra Safronova; Alessandra Araujo; Ellie T Camanzo; Taylor J Moon; Michael R Elliott; Daniel P Beiting; Felix Yarovinsky
Journal:  Nat Immunol       Date:  2018-11-19       Impact factor: 25.606

View more
  14 in total

Review 1.  PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii.

Authors:  Mojgan Allahyari
Journal:  Acta Parasitol       Date:  2022-01-11       Impact factor: 1.440

Review 2.  The role of IL-12 in stimulating NK cells against Toxoplasma gondii infection: a mini-review.

Authors:  Sepideh Mahmoudzadeh; Hojjatollah Nozad Charoudeh; Cláudia Silva Marques; Saeed Bahadory; Ehsan Ahmadpour
Journal:  Parasitol Res       Date:  2021-06-10       Impact factor: 2.289

Review 3.  Toxoplasma gondii infection and its implications within the central nervous system.

Authors:  Sumit K Matta; Nicholas Rinkenberger; Ildiko R Dunay; L David Sibley
Journal:  Nat Rev Microbiol       Date:  2021-02-24       Impact factor: 60.633

4.  Toxoplasma TgATG9 is critical for autophagy and long-term persistence in tissue cysts.

Authors:  David Smith; Geetha Kannan; Isabelle Coppens; Fengrong Wang; Hoa Mai Nguyen; Aude Cerutti; Einar B Olafsson; Patrick A Rimple; Tracey L Schultz; Nayanna M Mercado Soto; Manlio Di Cristina; Sébastien Besteiro; Vern B Carruthers
Journal:  Elife       Date:  2021-04-27       Impact factor: 8.140

Review 5.  Vaccines in Congenital Toxoplasmosis: Advances and Perspectives.

Authors:  Mariana Barros; Daniela Teixeira; Manuel Vilanova; Alexandra Correia; Natercia Teixeira; Margarida Borges
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

6.  Murine Irgm Paralogs Regulate Nonredundant Functions To Execute Host Defense to Toxoplasma gondii.

Authors:  Jacob Dockterman; Brian E Fee; Gregory A Taylor; Jörn Coers
Journal:  Infect Immun       Date:  2021-08-02       Impact factor: 3.441

7.  ISG15 Connects Autophagy and IFN-γ-Dependent Control of Toxoplasma gondii Infection in Human Cells.

Authors:  Jaya Bhushan; Joshua B Radke; Yi-Chieh Perng; Michael Mcallaster; Deborah J Lenschow; Herbert W Virgin; L David Sibley
Journal:  mBio       Date:  2020-10-06       Impact factor: 7.867

8.  Effective Nanoparticle-Based Nasal Vaccine Against Latent and Congenital Toxoplasmosis in Sheep.

Authors:  Céline Ducournau; Nathalie Moiré; Rodolphe Carpentier; Pauline Cantin; Clément Herkt; Isabelle Lantier; Didier Betbeder; Isabelle Dimier-Poisson
Journal:  Front Immunol       Date:  2020-09-09       Impact factor: 7.561

9.  High Prevalence of Toxoplasma gondii Infection in Type I Diabetic Patients.

Authors:  Qasem Asgari; Mohammad Hossein Motazedian; Amir Khazanchin; Davood Mehrabani; Shahrbanou Naderi Shahabadi
Journal:  J Parasitol Res       Date:  2021-02-09

10.  Overexpression screen of interferon-stimulated genes identifies RARRES3 as a restrictor of Toxoplasma gondii infection.

Authors:  Nicholas Rinkenberger; Michael E Abrams; Sumit K Matta; John W Schoggins; Neal M Alto; L David Sibley
Journal:  Elife       Date:  2021-12-06       Impact factor: 8.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.